The drug developer said that the biomarker panel will form the basis of a planned point-of-care test for acute respiratory distress syndrome.
The company also received a contract from the Henry M. Jackson Foundation for a separate sepsis test.
Treatment of Chagas disease can be lengthy and there is currently no available method to confirm whether a patient has been cured, according to the firm.
During an NIH meeting, researchers from four newborn sequencing research projects discussed results of their studies and future implications.
Abbott's test is designed to detect two proteins — GFAP and UCH-L1 — that are released from the brain into the bloodstream following brain injury.
The device can process high-volume sputum samples for PCR-based Mycobacterium tuberculosis detection at smear-negative, culture-positive levels.
The developers are exploring clinical applications with a view to making a platform available in a few years for testing at the point of care and in remote settings.
In a newly published study, an algorithm developed at NIH shows promise for improving early detection of cervical cancer in low-resource areas, where 80 percent of cases occur.
New drugs, tests, and policies suggest steady and continued future growth in the space, though public awareness of personalized medicine continues to lag.
Excluding IPOs, the funding environment for private venture-backed financing Dx deals in the US and Europe was remarkably similar in 2018 to 2017, according to Silicon Valley Bank.